2 weeks Ago By ABMN Staff
Lynx1 Capital Management LP trimmed its stake in Bionomics Limited ( NASDAQ:BNOX – Free Report ) by 26.4% during the second quarter, HoldingsChannel.com reports.
The institutional investor owned 599,673 shares of the company’s stock after selling 214,794 shares during the quarter. Bionomics accounts for approximately 0.2% of Lynx1 Capital Management LP’s holdings, making the stock its 12th biggest holding.
Lynx1 Capital Management LP owned about 0.07% of Bionomics worth $460,000 as of its most recent filing with the SEC. Separately, Armistice Capital LLC acquired a new stake in Bionomics in the 2nd quarter valued at approximately $941,000.
Institutional investors and hedge funds own 15.90% of the company’s stock. Wall Street Analyst Weigh In Separately, HC Wainwright reiterated a “buy” rating and set a $8.
00 price target on shares of Bionomics in a research report on Thursday, August 1st. Bionomics Price Performance Bionomics stock opened at $0.63 on Friday.
The company’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.81.
Bionomics Limited has a 52 week low of $0.50 and a 52 week high of $6.41.
Bionomics Company Profile ( Free Report ) Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. Recommended Stories Want to see what other hedge funds are holding BNOX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Bionomics Limited ( NASDAQ:BNOX – Free Report ). Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter .
.
